Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 157,721 |
|
|||||
| News | - | ||||||
| Day High | 1.59 | Low High |
|||||
| Day Low | 1.45 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Scynexis Inc | SCYX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.07 | 4.76% | 1.54 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.45 | 1.45 | 1.59 | 1.54 | 1.47 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 828 | 157,721 | US$ 1.51 | US$ 238,700 | - | 1.35 - 3.87 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:00:07 | 18 | US$ 1.54 | USD |
Scynexis Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 57.3M | 37.21M | - | 140.14M | 67.04M | 1.80 | 0.85 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Scynexis News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SCYX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.41 | 1.6058 | 1.39 | 1.49 | 112,507 | 0.13 | 9.22% |
| 1 Month | 1.52 | 1.86 | 1.37 | 1.58 | 200,044 | 0.02 | 1.32% |
| 3 Months | 2.14 | 2.17 | 1.35 | 1.63 | 204,393 | -0.60 | -28.04% |
| 6 Months | 1.72 | 2.37 | 1.35 | 1.74 | 208,501 | -0.18 | -10.47% |
| 1 Year | 2.87 | 3.87 | 1.35 | 2.38 | 300,289 | -1.33 | -46.34% |
| 3 Years | 7.44 | 11.30 | 1.15 | 3.88 | 404,242 | -5.90 | -79.30% |
| 5 Years | 1.68 | 11.30 | 0.50 | 3.16 | 468,444 | -0.14 | -8.33% |
Scynexis Description
| SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. |
